Semaglutide versus liraglutide head to head: reading STEP 8 carefully

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

Post #4 put the caveat in the right place and I want to underline it.

The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.

A single observation, in a thread that deserves better than single observations.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

The number is defensible. The precision I gave it is not.

Nausea is dose-related and adaptation-related, and both are true at once. The pattern most people describe is a return of symptoms at each escalation followed by adaptation, rather than a single course of adaptation at the start.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

Anyone who has looked at this more carefully, please correct the record.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.

STEP 1 and STEP 4 are two different questions. The first asks what happens when treatment is added; the second asks what happens when it is withdrawn after a run-in. Quoting the first as evidence about maintenance is the commonest misreading of the programme.

None of the above is medical advice and I am not qualified to give any.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

I would hold that lightly until someone with a larger sample weighs in.

Semaglutide versus liraglutide sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.